New 'Off-the-Shelf' CAR-T therapy takes on Hard-to-Treat myeloma
NCT ID NCT07622862
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing DQ1001, a ready-made CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is designed for patients whose multiple myeloma has returned or stopped responding to at least three prior treatments. The study will enroll 16 adults aged 18-70 to check safety and see if the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DQ1001 (a universal allogeneic CAR-T cell therapy targeting BCMA and GPRC5D)
What this could lead to
If successful, this could provide a new treatment option for patients with hard-to-treat multiple myeloma, potentially improving response rates and extending survival.
What could go wrong
This is a very early (Phase 1) trial with only 16 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects like cytokine release syndrome or graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.